Esperion Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ESPR and other ETFs, options, and stocks.

About ESPR

Esperion Therapeutics, Inc. is a pharmaceutical company, which engages in the development and commercialization of oral therapies for elevated low-density lipoprotein cholesterol. The firm offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. 

CEO
Sheldon L. Koenig
CEOSheldon L. Koenig
Employees
304
Employees304
Headquarters
Ann Arbor, Michigan
HeadquartersAnn Arbor, Michigan
Founded
1998
Founded1998
Employees
304
Employees304

ESPR Key Statistics

Market cap
501.03M
Market cap501.03M
Price-Earnings ratio
-4.84
Price-Earnings ratio-4.84
Dividend yield
Dividend yield
Average volume
7.99M
Average volume7.99M
High today
$2.68
High today$2.68
Low today
$2.48
Low today$2.48
Open price
$2.62
Open price$2.62
Volume
5.49M
Volume5.49M
52 Week high
$3.94
52 Week high$3.94
52 Week low
$0.6925
52 Week low$0.6925

ESPR News

Simply Wall St 12h
Esperion Therapeutics: Evaluating Valuation After $75 Million Equity Raise and Recent Share Price Volatility

Esperion Therapeutics (ESPR) just completed a $75 million follow-on equity offering, issuing 30 million shares at $2.50 each. This capital raise comes at a key...

Esperion Therapeutics: Evaluating Valuation After $75 Million Equity Raise and Recent Share Price Volatility
TipRanks 22h
Esperion Announces Public Offering to Raise $70.2 Million

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to...

TipRanks 2d
Esperion announces common stock offering, no amount given

Esperion (ESPR) Therapeutics announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares of common stock in...

Analyst ratings

63%

of 8 ratings
Buy
62.5%
Hold
25%
Sell
12.5%

More ESPR News

TipRanks 6d
Esperion’s Strategic Legal Settlements and Regulatory Advancements Drive Buy Rating

In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Esperion, with a price target of $16.00. Elevate Your Investing Str...

TipRanks 6d
Esperion reaches settlement agreement with ANDA filer, Dr. Reddy’s

Esperion (ESPR) announced that it has entered into a settlement agreement with Dr. Reddy’s Laboratories (RDY) and its affiliate Dr. Reddy’s Laboratories. This a...

People also own

Based on the portfolios of people who own ESPR. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.